ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2019
Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Proton beam therapy indications in the Kingdom of Saudi Arabia: A SARO clinical practice guideline.Saudi medical journal · 2025Guideline
- Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiotherapy in the management of patients with diffuse low grade glioma in adults: update.Journal of neuro-oncology · 2025Guideline
- Charged particle therapy for high-grade gliomas in adults: a systematic review.Radiation oncology (London, England) · 2023Pooled it
- Influences on cognitive outcomes in adult patients with gliomas: A systematic review.Frontiers in oncology · 2022Pooled it
- Survival, late toxicity and ability to return to work after proton radiotherapy for low-grade gliomas.Journal of neuro-oncology · 2026Article
- Proton therapy in Spain: SEOR-SPROMP multidisciplinary recommendations developed through a RAND/UCLA consensus process.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Trade-offs in proton and photon radiotherapy for pituitary adenomas.Physics and imaging in radiation oncology · 2026Article
- Prospectively assessed hypothalamic-pituitary dysfunction after proton therapy in adults with head and neck, skull base and brain tumors.Scientific reports · 2025Article
- Proton therapy for adult type IDH-mutated glioma: Proglio-1, a multicenter retrospective study.Radiation oncology (London, England) · 2025Article
- A scoping review of proton radiation therapy and mutant-isocitrate dehydrogenase-inhibitors in IDH mutated lower-grade gliomas: pushing beyond surrogate end-points.Acta neurochirurgica · 2025Article
- A review of proton beam therapy's role in glioma management.Medicine · 2025Review
- Radiotherapy-induced Hypothalamic-Pituitary axis dysfunction in adult Brain, head and neck and skull base tumor patients - A systematic review and Meta-Analysis.Clinical and translational radiation oncology · 2025Review
- Article
- Symptom management in isocitrate dehydrogenase mutant glioma.Neuro-oncology practice · 2025Review
- Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3.Frontiers in oncology · 2025Article
- Article
- Unique brain injury patterns after proton vs photon radiotherapy for WHO grade 2-3 gliomas.The oncologist · 2024Article
- Treatment Options for IDH-Mutant Malignant Gliomas.Current treatment options in oncology · 2024Review
- Low-Grade Glioma Clinical Trials in the United States: A Systematic Review.Life (Basel, Switzerland) · 2024Review
- Dosimetric comparison of advanced radiation techniques for scalp-sparing in low-grade gliomas.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients with low-grade gliomas (LGG) can survive years with their illness. Proton radiotherapy (PRT) can reduce off-target dose and decrease the risk of treatment-related morbidity. We examined long-term morbidity following proton therapy in this updated prospective cohort of patients with LGG.
methodsTwenty patients with LGG were enrolled prospectively and received PRT to 54 Gy(RBE) in 30 fractions. Comprehensive baseline and longitudinal assessments of toxicity, neurocognitive and neuroendocrine function, quality of life, and survival outcomes were performed up to 5 years following treatment.
resultsSix patients died (all of disease) and six had progression of disease. Median follow-up was 6.8 years for the 14 patients alive at time of reporting. Median progression-free survival (PFS) was 4.5 years. Of tumors tested for molecular markers, 71% carried the IDH1-R132H mutation and 29% had 1p/19q co-deletion. There was no overall decline in neurocognitive function; however, a subset of five patients with reported cognitive symptoms after radiation therapy had progressively worse function by neurocognitive testing. Six patients developed neuroendocrine deficiencies, five of which received Dmax ≥20 Gy(RBE) to the hypothalamus-pituitary axis (HPA). Most long-term toxicities developed within 2 years after radiation therapy.
conclusionsThe majority of patients with LGG who received proton therapy retained stable cognitive and neuroendocrine function. The IDH1-R132H mutation was present in the majority, while 1p/19q loss was present in a minority. A subset of patients developed neuroendocrine deficiencies and was more common in those with higher dose to the HPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.